

Droncit®

(praziquantel)

Feline Cestocide Tablets

CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

Each Tablet Contains 23 mg Praziquantel

DESCRIPTION: Droncit® Feline Cestocide Tablets are sized for easy oral administration to either adult cats or kittens. The tablets may be crumbled and mixed with the feed.

INDICATIONS: Droncit® Feline Cestocide Tablets are indicated for the removal of the following feline cestodes: *Dipylidium caninum* and *Taenia taeniaeformis*.

CONTRAINDICATIONS: There are no known contraindications to the use of praziquantel in cats.

ACTION: Droncit® (praziquantel) is absorbed, metabolized in the liver and excreted in the bile. Upon entering the digestive tract from the bile, cestocidal activity is exhibited.¹

Following exposure to praziquantel, the tapeworm loses its ability to resist digestion by the mammalian host. Because of this, whole tapeworms, including the scolex, are very rarely passed after administration of praziquantel. In many instances only disintegrated and partially digested pieces of tapeworms will be seen in the stool. The majority of tapeworms killed are digested and are not found in the feces.

USE DIRECTIONS: Droncit® Feline Cestocide Tablets may be administered directly per os or crumbled and mixed with the feed. The recommended dosage of praziquantel varies according to body weight. Smaller animals require a relatively larger dosage because of their higher metabolic rate. The optimum dose for each individual animal will be achieved by utilizing the following dosage schedule:

Cats and Kittens*

4 pounds and under	1/2 tablet
5-11 pounds	1 tablet
Over 11 pounds	1 1/2 tablets

*Not intended for use in kittens less than 6 weeks of age.

FASTING: The recommended dosage of praziquantel is not affected by the presence or absence of food in the gastrointestinal tract, therefore, **FASTING IS NEITHER NECESSARY NOR RECOMMENDED.**

RETREATMENT: For those animals maintained on premises where reinfections are likely to occur, clients should be instructed in the steps necessary to prevent reinfection; otherwise, retreatment may

be necessary. This is especially true in cases of *Dipylidium caninum* infections where reinfection is almost certain to occur if fleas are not removed from the animal and its environment.

ANIMAL SAFETY: The safety index has been derived from controlled safety evaluations, clinical trials and prior approved use in foreign countries.

Dosages of 5 times the labeled rate at 14 day intervals to cats as young as 5 1/2 weeks did not produce clinical signs of toxicity. No significant clinical chemistry, hematological, or histopathological changes occurred. Symptoms of gross overdosage include vomiting, salivation, diarrhea and depression.

PREGNANCY: Droncit® (praziquantel) has been tested in breeding and pregnant cats. No adverse effects were noted.

ADVERSE REACTIONS: One instance of diarrhea and one of salivation (1.5%) were reported during the field trials in which 135 cats were administered Droncit® Feline Cestocide.

For medical emergencies or to report adverse reactions, call 1-800-422-9874.

WARNING: Keep out of the reach of children. Not for human use.

For customer service or to obtain product information, including Material Safety Data Sheet, call 1-800-633-3796.

HOW SUPPLIED: Bottle of 50 and 150 scored tablets. Each scored tablet contains 23 mg praziquantel.

Product Code 08713165-182999 — 50 Tablets

Code 08713211-185599—150 Tablets

REFERENCES:

¹ Andrews, P. Pharmacokinetic Studies with Droncit in Animals Using a Biological Assay. *Veterinary Medical Review* 2/76: 154-165.

Droncit is a Reg. TM of the parent company of Bayer AG, Leverkusen.



Bayer

Bayer HealthCare LLC, Animal Health Division
Shawnee Mission, Kansas 66201 U.S.A.

NADA 111-798, Approved by FDA

Bayer, the Bayer Cross, and Droncit are trademarks of Bayer.

Made in U.S.A.

08954391, R.1

©2007 Bayer HealthCare LLC

July, 2007

13509

ITS081310